Nipro Vialex – 26th January 2025
PCI – 7th June 2024
Temax_Krautz

Current Edition

Nasal & Pulmonary Drug Development
Novo Nordisk 20 March 2024, 11:21
Carterra – 24th March 2025

ICR cancer drug NXP800 to enter Phase I trials

An investigational drug called NXP800, discovered at the Cancer Research UK Cancer Therapeutics Unit at London’s Institute of Cancer Research (ICR), is to enter Phase I clinical trials in patients with advanced cancers.

The Phase I study will begin later this year and is being funded by oncology-focused biopharmaceutical company Nuvectis Pharma.

The investigational oral drug inhibits the Heat Shock Factor-1 (HSF1) pathway, and in pre-clinical studies was shown to potently block human cancer cell growth in culture and cause regression of tumours in mice – with hard-to-treat ovarian clear cell carcinoma (OCCC) and endometrioid ovarian cancers being the most sensitive to treatment.

Nuvectis has licensed worldwide development and commercialisation rights to the HSF1 drug candidate from its previous commercial investor, the CRT Pioneer Fund (CPF) managed by Sixth Element Capital.

Professor Udai Banerji, deputy director of drug development at the ICR and The Royal Marsden NHS Foundation Trust, commented: “This Phase I trial will aim to establish a safe dose and dosing schedule for NXP800, as well as provide initial evidence of its clinical activity in a range of cancer types – and we hope that it will lead on to late-stage clinical development.”

Scott Pharma – 25.03.2025
SMI – 24/03/2025
Chemspec Europe – 27.02.2025
PHARMAP: Mon 14 October 2024, 10.36
FujiFilm Skyscraper: 26th November 2024
Woolcool 26 March 2024, 16:16
Biopharma group 6 March 2024, 09:40
EyeC 18 March 2024, 13:10
L.B. Bohle – 08.04.2025